Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ACLX

ACLX - Arcellx, Inc. Stock Price, Fair Value and News

65.80USD-1.52 (-2.26%)Market Closed
Watchlist

Market Summary

USD65.80-1.52
Market Closed
-2.26%

ACLX Alerts

  • 2 major insider sales recently.
  • Big jump in Earnings (Y/Y)

ACLX Stock Price

View Fullscreen

ACLX RSI Chart

ACLX Valuation

Market Cap

3.3B

Price/Earnings (Trailing)

-46.31

Price/Sales (Trailing)

29.68

EV/EBITDA

-42.29

Price/Free Cashflow

17.59

ACLX Price/Sales (Trailing)

ACLX Profitability

EBT Margin

-63.48%

Return on Equity

-14.56%

Return on Assets

-8.57%

Free Cashflow Yield

5.69%

ACLX Fundamentals

ACLX Revenue

Revenue (TTM)

110.3M

ACLX Earnings

Earnings (TTM)

-70.7M

Earnings Growth (Yr)

150.89%

Earnings Growth (Qtr)

150.45%

Breaking Down ACLX Revenue

Last 7 days

-5.4%

Last 30 days

10.5%

Last 90 days

11.2%

Trailing 12 Months

102.3%

How does ACLX drawdown profile look like?

ACLX Financial Health

Current Ratio

6.06

ACLX Investor Care

Shares Dilution (1Y)

11.02%

Diluted EPS (TTM)

-1.47

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023000110.3M

Tracking the Latest Insider Buys and Sells of Arcellx, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 12, 2024
elghandour rami
sold
-719,948
64.4595
-11,169
see remarks
Feb 12, 2024
heery christopher
sold
-191,251
64.4595
-2,967
chief medical officer
Feb 09, 2024
heery christopher
sold
-233,811
63.3977
-3,688
chief medical officer
Feb 09, 2024
elghandour rami
sold
-880,340
63.3977
-13,886
see remarks
Feb 08, 2024
elghandour rami
sold
-810,451
62.2945
-13,010
see remarks
Feb 08, 2024
heery christopher
sold
-215,290
62.2945
-3,456
chief medical officer
Feb 07, 2024
elghandour rami
acquired
-
-
70,211
see remarks
Feb 07, 2024
heery christopher
acquired
-
-
22,555
chief medical officer
Jan 04, 2024
elghandour rami
sold
-1,606,800
55.2679
-29,073
see remarks
Jan 04, 2024
gilson michelle
sold
-470,551
55.2679
-8,514
chief financial officer

1–10 of 50

Which funds bought or sold ACLX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
added
0.66
378,560
1,058,160
-%
Feb 26, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
sold off
-100
-662,000
-
-%
Feb 26, 2024
PERCEPTIVE ADVISORS LLC
added
14.59
109,938,000
252,237,000
5.63%
Feb 20, 2024
Able Wealth Management LLC
new
-
1,221
1,221
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
34.51
36,325,000
69,941,000
0.01%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
sold off
-100
-657,000
-
-%
Feb 15, 2024
Legal & General Group Plc
reduced
-0.35
580,165
1,651,790
-%
Feb 15, 2024
BARCLAYS PLC
added
50.17
4,091,000
7,183,000
-%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
333
333
-%
Feb 15, 2024
Virtus ETF Advisers LLC
reduced
-30.71
6,711
100,178
0.06%

1–10 of 44

Are Funds Buying or Selling ACLX?

Are funds buying ACLX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ACLX
No. of Funds

Unveiling Arcellx, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
paradigm biocapital advisors lp
7.0%
3,658,624
SC 13G/A
Feb 14, 2024
perceptive advisors llc
8.8%
4,544,809
SC 13G/A
Feb 13, 2024
suvretta capital management, llc
5.0%
2,435,974
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G
Jan 29, 2024
blackrock inc.
6.2%
3,018,538
SC 13G
Dec 28, 2023
gilead sciences, inc.
12.9%
6,720,803
SC 13G/A
Dec 18, 2023
sr one capital management, llc
6.46%
3,146,630
SC 13D/A
Jul 21, 2023
paradigm biocapital advisors lp
5.05%
2,422,700
SC 13G
Jun 23, 2023
new enterprise associates 15, l.p.
7.8%
3,745,262
SC 13D/A
Jun 02, 2023
sr one capital management, llc
8.22%
3,946,630
SC 13D/A

Recent SEC filings of Arcellx, Inc.

View All Filings
Date Filed Form Type Document
Feb 28, 2024
10-K
Annual Report
Feb 28, 2024
8-K
Current Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 12, 2024
4
Insider Trading
Feb 12, 2024
4
Insider Trading
Feb 09, 2024
4
Insider Trading
Feb 09, 2024
SC 13G
Major Ownership Report
Feb 09, 2024
4
Insider Trading

Peers (Alternatives to Arcellx, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
35.3B
6.8B
-16.59% -47.80%
-7.48
5.15
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.0B
1.8B
-23.99% -31.71%
-43.22
10.41
76.23% 61.08%
16.3B
2.4B
-4.89% -18.90%
97.14
6.73
15.42% 18.43%
13.1B
3.7B
-7.62% -26.87%
21.93
3.55
8.87% 75.42%
MID-CAP
8.3B
396.6M
-2.06% 34.31%
-15.62
20.82
425.83% 18.94%
6.0B
-
-3.85% 226.12%
-9.59
60.35
54.84% -25.61%
4.2B
240.7M
-19.08% -10.99%
-14.19
17.5
-1.03% -92.09%
4.1B
726.4M
-12.60% 32.37%
-66.62
5.62
40.45% 71.62%
3.9B
270.6M
8.92% 47.81%
-16.43
14.52
440.80% -27.84%
SMALL-CAP
1.9B
398.2M
-3.38% -9.50%
26.46
4.74
85.90% -14.05%
687.2M
983.7M
-9.17% -57.89%
-1.26
0.7
-50.36% 17.16%
201.6M
4.9M
-14.18% -58.18%
-1.22
41.23
-57.57% 50.48%
135.5M
881.7K
289.54% 381.25%
-2.86
112.79
-77.61% -13.74%
4.3M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Arcellx, Inc. News

Latest updates
MarketBeat23 minutes ago
Zacks Investment Research25 hours ago
Seeking Alpha27 hours ago
AmericanBankingNEWS25 Feb 202401:27 pm

Arcellx, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q1
Revenue322.2%63,148,00014,957,00014,302,00017,912,000
Operating Expenses-19.5%48,149,00059,819,00043,862,00048,369,000
  S&GA Expenses20.9%19,365,50016,012,00015,535,00015,437,000
  R&D Expenses-34.3%28,783,50043,807,00028,327,00032,932,000
EBITDA Margin-Infinity%-0.61---
Income Taxes10616.7%631,000-6,000-300,000329,000
Earnings Before Taxes152.0%20,466,000-39,342,000-24,136,000-27,015,000
EBT Margin-Infinity%-0.63---
Net Income150.4%19,844,000-39,336,000-23,854,000-27,344,000
Net Income Margin-Infinity%-0.64---
Free Cashflow393.7%52,955,000-18,029,000-29,843,000181,062,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Assets34.3%82561462462331433737524712911193.0075.0058.00
  Current Assets45.8%716491558571267290325224113---49.00
    Cash Equivalents216.3%39912630427564.0057.0016512731.0070.0014411847.00
  Net PPE13.1%43.0038.0022.0014.0011.0010.0010.0010.0010.00---5.00
Liabilities-2.4%34034833031910910151.0019.0017.0014.0012.0010.007.00
  Current Liabilities-31.7%11817315616657.0045.0024.0014.0015.00---5.00
Shareholder's Equity82.4%4852662943042052363242289.006.004.002.001.00
  Retained Earnings4.8%-389-409-370-346-318-279-186-156-130----65.14
  Additional Paid-In Capital29.4%8746756646505245165113849.00---1.00
Shares Outstanding7.4%52.0049.0048.0048.0044.0044.0029.0021.00-0.000.000.000.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Cashflow From Operations676.6%58.00-10.10-22.61182-27.52-16.65-22.55-32.59-21.55-12.22-10.96-9.51-
  Share Based Compensation0.0%11.0011.0010.0010.006.005.006.004.003.002.001.001.00-
Cashflow From Investing113.1%21.00-16051.00-66.7734.00-81.42-59.23-10.64-17.66-61.07-0.18-1.07-
Cashflow From Financing3880.1%189-4.990.0095.001.00-9.711211400.00-0.4737.0082.00-

ACLX Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]  
Collaboration revenue from related party$ 110,319 
Operating expenses:  
Research and development133,849$ 149,555
General and administrative66,35041,704
Total operating expenses200,199191,259
Loss from operations(89,880)(191,259)
Other income (expense):  
Interest and other income (expense), net23,6954,300
Interest expense(3,842)(1,720)
Total other income, net19,8532,580
Loss before income taxes(70,027)(188,679)
Income tax (expense) benefit(663) 
Net loss(70,690)(188,679)
Other comprehensive loss:  
Unrealized gain (loss) on marketable securities768(201)
Comprehensive loss$ (69,922)$ (188,880)
Net loss per share attributable to common stockholders - basic$ (1.47)$ (5.19)
Net loss per share attributable to common stockholders - diluted$ (1.47)$ (5.19)
Weighted-average common shares outstanding - basic48,061,45036,355,758
Weighted-average common shares outstanding - diluted48,061,45036,355,758

ACLX Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Assets, Current [Abstract]  
Cash and cash equivalents$ 394,583$ 64,179
Marketable securities307,434190,656
Restricted cash, current1,9030
Prepaid expenses and other current assets12,44312,028
Total current assets716,363266,863
Restricted cash, non-current2,4182,501
Marketable securities, non-current27,1680
Property and equipment, net42,72811,231
Operating lease right-of-use assets27,09928,659
Prepaid research and development expenses and other long-term assets9,3564,563
Total assets825,132313,817
Current liabilities:  
Accounts payable2,6199,053
Accrued liabilities18,30211,679
Operating lease liabilities, current portion7,5012,901
Finance lease liabilities, current portion39,28333,060
Less: current portion50,533 
Total current liabilities118,23856,693
Operating lease liabilities, net of current portion50,84131,299
Finance lease liabilities, net of current portion 20,871
Noncurrent portion170,6730
Total liabilities339,752108,863
Commitments and Contingencies (Note 11)
Stockholders' equity  
Common stock, par value of $0.001 per share; 1,000,000,000 shares authorized and 52,280,077 shares issued and outstanding as of December 31, 2023; 1,000,000,000 shares authorized and 44,105,981 shares issued and outstanding as of December 31, 20225244
Additional paid-in capital874,261523,921
Accumulated other comprehensive income (loss)547(221)
Accumulated Deficit(389,480)(318,790)
Total stockholders' equity485,380204,954
Total liabilities and stockholders' equity$ 825,132$ 313,817
ACLX
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and product candidates for solid tumor programs. It has strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize CART-ddBCMA. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
 CEO
 WEBSITEarcellx.com
 EMPLOYEES98

Arcellx, Inc. Frequently Asked Questions


What is the ticker symbol for Arcellx, Inc.? What does ACLX stand for in stocks?

ACLX is the stock ticker symbol of Arcellx, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arcellx, Inc. (ACLX)?

As of Thu Feb 29 2024, market cap of Arcellx, Inc. is 3.27 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACLX stock?

You can check ACLX's fair value in chart for subscribers.

What is the fair value of ACLX stock?

You can check ACLX's fair value in chart for subscribers. The fair value of Arcellx, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Arcellx, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACLX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Arcellx, Inc. a good stock to buy?

The fair value guage provides a quick view whether ACLX is over valued or under valued. Whether Arcellx, Inc. is cheap or expensive depends on the assumptions which impact Arcellx, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACLX.

What is Arcellx, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 29 2024, ACLX's PE ratio (Price to Earnings) is -46.31 and Price to Sales (PS) ratio is 29.68. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACLX PE ratio will change depending on the future growth rate expectations of investors.